LIVEN

⚡ Flash Summary

Liven Pharma Limited has announced a book closure for the issuance of right shares. The share transfer books will be closed from November 24th, 2025, to November 25th, 2025, to determine the entitlement of right shares. Transfers received by November 23rd, 2025, will be considered for the determination of entitlement. This action complies with the PSX Rule Book, and the notice will be published in Pakistani media.

📌 Key Takeaways

• 🗓️ Book closure dates: November 24th – 25th, 2025.
• 🏦 Purpose: Determining right share entitlement.
• ➡️ Announcement reference date: September 12th, 2025.
• 🏢 Share registrar: M/S F.D. Registrar Services SMC (Pvt.) Ltd.
• 📍 Registrar address: Saima Trade Tower A, I.I. Chundrigar Road, Karachi.
• ⏳ Transfer deadline: November 23rd, 2025.
• 📜 Compliance: Clause 5.6.9 (b) of PSX Rule Book.
• 📰 Publication: Pakistan Observer and Daily Pakistan on November 13th, 2025.
• 👤 Contact: Kaashif Hussain Siddiqie, CEO.
• 🏢 Company: Liven Pharma Limited.
• ✔️ The company aims to allocate right shares effectively.
• 🚦 Shareholders must ensure timely transfer to qualify.
• 📢 Exchange informed to notify TRE Certificate holders.

🎯 Investment Thesis

HOLD. The announcement relates to a procedural event (book closure) for a right shares issue. A comprehensive investment thesis needs thorough fundamental analysis of Liven Pharma.

⚡ Flash Summary

LIVEN announced: Board Meeting For Consideration of Annual Accounts For The Year Ended June 30, 2025.. Basic analysis suggests neutral sentiment. Professional review recommended.

📌 Key Takeaways

• LIVEN made announcement: Board Meeting For Consideration of Annual Accounts For The Year Ended June 30, 2025.
• Automated analysis: HOLD signal detected
• Signal strength: 5/10
• This is basic analysis – manual review recommended
• Professional CFA analysis unavailable

🎯 Investment Thesis

Basic HOLD indication for LIVEN. Manual verification required.

⚡ Flash Summary

Liven Pharma Limited has announced its 34th Annual General Meeting (AGM) to be held on November 26, 2025, to confirm minutes, adopt financial statements for the year ended June 30, 2025, and appoint auditors for the year ending June 30, 2026. The meeting will address ordinary business, including auditor re-appointment. Special business includes the approval for circulation of the annual report via weblink and QR code, aligning with regulatory requirements. Shareholders are encouraged to participate electronically, with specific procedures outlined for registration, proxy appointments, and e-voting.

📌 Key Takeaways

• 🗓️ The 34th AGM will be held on **November 26, 2025**, at 11:00 AM.
• 📍 The meeting will take place at the company’s registered office at **49-km Lahore-Multan Road, Pakistan**.
• ✔️ Agenda includes confirming the minutes of the previous AGM held on **October 25, 2024**.
• 📄 Shareholders will receive and consider the Annual Audited Financial Statements for the year ended **June 30, 2025**.
• 👨‍💼 Auditors will be appointed for the year ending **June 30, 2026**, with their remuneration to be fixed.
• ✅ Re-appointment of retiring auditors **M/s. Reanda Haroon Zakaria Aamir Salman Rizwan & Company** is recommended.
• 🌐 The annual report will be circulated through a **weblink and QR enabled code**.
• 🔗 The Annual Report for the year ended June 30, 2025 is available on the company’s website.
• 🚫 Share transfer books will be closed from **November 19, 2025 to November 26, 2025**.
• ✉️ Transfers must be received by **5 pm on November 18, 2025**, to be treated in time.
• 🗳️ Members appearing in the register as of **November 18, 2025**, are entitled to attend and vote.
• 🤝 Members can appoint a proxy, with forms to be deposited **48 hours before the meeting**.
• 💻 Shareholders can attend via video-conferencing; registration required via email.
• 📧 Email addresses for registration and inquiries: **info@liven-pharma.com and fdregistrar@yahoo.com**.

🎯 Investment Thesis

Based solely on this announcement, a HOLD recommendation is appropriate. The AGM is a routine event, and the focus remains on governance and compliance rather than strategic initiatives. A more informed investment decision would require a detailed analysis of the adopted financial statements, management’s outlook, and other relevant factors. A price target and timeline cannot be determined without further financial information.

⚡ Flash Summary

LIVEN announced: Financial Result For the Year Ended June 30, 2025. Basic analysis suggests neutral sentiment. Professional review recommended.

📌 Key Takeaways

• LIVEN made announcement: Financial Result For the Year Ended June 30, 2025
• Automated analysis: HOLD signal detected
• Signal strength: 5/10
• This is basic analysis – manual review recommended
• Professional CFA analysis unavailable

🎯 Investment Thesis

Basic HOLD indication for LIVEN. Manual verification required.

⚡ Flash Summary

LIVEN announced: Financial Results Summary for Year ended 2025. Basic analysis suggests neutral sentiment. Professional review recommended.

📌 Key Takeaways

• LIVEN made announcement: Financial Results Summary for Year ended 2025
• Automated analysis: HOLD signal detected
• Signal strength: 5/10
• This is basic analysis – manual review recommended
• Professional CFA analysis unavailable

🎯 Investment Thesis

Basic HOLD indication for LIVEN. Manual verification required.